Integrated Biopharma Inc. (INBP) intrinsic value & 10-year financials
Integrated Biopharma Inc. (INBP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 2.9% a year to $54.4M, with an average return on invested capital of -24.2%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.18
- Market cap
- $5.6M
- Revenue (FY2025)
- $54.4M
- Revenue growth (10-yr CAGR)
- 2.9%
- ROIC (10-yr avg)
- -24.2%
- Free cash flow (FY2025)
- $1.9M
INBP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $54.4M | $808.0K | $0.03 | $1.9M | 3.7% | 5.7% |
| FY2024 | $50.3M | $112.0K | $0.00 | $390.0K | 0.5% | 0.7% |
| FY2023 | $50.7M | -$34.0K | $0.00 | $1.1M | 0.2% | 0.3% |
| FY2022 | $56.2M | $3.8M | $0.12 | $3.6M | 4.9% | 14.8% |
| FY2021 | $63.6M | $8.0M | $0.25 | $2.8M | 9.1% | 38.9% |
| FY2020 | $52.8M | $4.1M | $0.13 | $1.1M | 6.2% | 32.1% |
| FY2019 | $50.0M | $1.7M | $0.06 | -$86.0K | 5.4% | 64.4% |
| FY2018 | $43.7M | $679.0K | $0.02 | $921.0K | 3.9% | -129.8% |
| FY2017 | $47.0M | $2.3M | $0.10 | $70.0K | 6.8% | -200.5% |
| FY2016 | $42.2M | $958.0K | $0.05 | -$703.0K | 5.0% | -68.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
INTEGRATED BIOPHARMA INC has demonstrated mature, steady growth, with revenue compounding at 2.8% annually over the past decade.
INTEGRATED BIOPHARMA INC has historically struggled to out-earn its cost of capital, averaging just -4.3% ROIC.
INTEGRATED BIOPHARMA INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, INTEGRATED BIOPHARMA INC is modeled at -5.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.07 per share.